TRIAL BETTER
See what we’re up to – and what we have to say – in today’s dynamic market.
In this series, learn how to make changes to your oncology development program that improve data quality and accelerate the development of new cancer treatments.
Read MoreThis blog reviews the critical role advanced and customized training plays in improving data quality in clinical trials where patient-reported outcome (PRO) and observer reported outcome (ObsRO) assessments support key efficacy endpoints.
Read MoreLearn how, by using an electronic solution to capture critical patient data, sponsors can meet their accelerated trial timelines while still maintaining data integrity during vaccine clinical trials.
Read MoreHere, we review the contents of an imaging charter, which clinical trial sponsors are encouraged to develop and adhere to in order to optimize the quality of imaging data obtained in clinical trials.
Read MoreThis blog focuses on imaging evaluations (e.g. CT/MRI) used as an outcome endpoint to determine efficacy when assessing novel cancer therapies.
Read MoreHere we review the rationale for using subspecialist readers to interpret medical images when used in support of clinical study endpoints.
Read MoreLearn how evolving technology is enabling remote research to expand so that previously excluded patient populations can now participate in clinical trials.
Read MoreTake quiz: blinded reader monitoring in imaging clinical trials
Read MoreIn this blog, we present the practices imaging providers should follow to ensure compliance with relevant regulations when imaging is used to capture safety or efficacy data in clinical trials.
Read MoreHere we review why the use of eCOA is recommended and how sponsors can benefit from leveraging electronic data capture in oncology, phase I/II and large-scale clinical trials.
Read MoreHere we review the distinct meanings and discernible differences between artificial intelligence, machine learning and deep learning and why, although related to each other, they are not interchangeable.
Read MoreIn this first of a series of when to use eCOA in clinical trials, we present examples of study types, endpoints and patient populations that deem the use of eCOA critical to the trial’s success.
Read MoreAnalyze the differences between centralized and local site-based reads, including their respective impact and value.
Read MoreToday’s common practice of using disparate systems to collect study data makes it difficult for researchers to manage trial performance and uncover valuable insights about the treatments they are developing. Learn how today’s trial oversight technology overcomes these challenges and improves trial efficiencies.
Read MoreUnderstand the two types of imaging process standards (medical practice and trial-specific) and learn how to determine which is appropriate for your clinical trial.
Read MoreHere we present current research on clinical benefits that have been demonstrated through the use of electronic PRO data capture – including improved survival – and review new findings on preference for electronic PRO data capture among patients with cancer.
Read MoreIn this second part of a series, we outline the factors sponsors need to consider when implementing Ambulatory Blood Pressure Monitoring during clinical trials to ensure the collection of valid and useful data for regulatory submissions.
Read MoreLearn how the use of standardized imaging protocols with appropriate radiological and clinical response assessments (based on tumor characteristics) can improve the robustness of clinical trial data and the chances to obtain positive results in pediatric neuro-oncology trials.
Read MoreLearn the different approaches to assessing Suicidal Ideation and Behavior (SIB) during clinical trials and how to ensure you’re meeting regulatory requirements and keeping patients safe.
Read MoreIn this first of a 2-part series on the importance of PRO data in oncology drug development, we review the latest regulatory guidances recommending the use of PROs in oncology trials.
Read More